2010
Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizures
Cao W, Glushakov A, Shah HP, Mecca AP, Sumners C, Shi P, Seubert CN, Martynyuk AE. Halogenated aromatic amino acid 3,5-dibromo-d-tyrosine produces beneficial effects in experimental stroke and seizures. Amino Acids 2010, 40: 1151-1158. PMID: 20839013, PMCID: PMC8396070, DOI: 10.1007/s00726-010-0739-4.Peer-Reviewed Original ResearchConceptsMiddle cerebral artery occlusionET-1 administrationInfarct volumePTZ administrationEndothelin-1Cardiovascular parametersOnset of MCAOCerebral artery occlusionArterial blood pressureCaspase-3-positive cellsSpontaneous locomotor activityNovel therapeutic directionArtery occlusionExperimental strokeNeurological deficitsBlood pressureSeizure scoreNeurological functionIntracerebral injectionIntraperitoneal injectionBolus injectionRat modelHeart rateControl animalsPositive cells
2009
Efficacy of 3,5‐dibromo‐L‐phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit
Cao W, Shah H, Glushakov A, Mecca A, Shi P, Sumners C, Seubert C, Martynyuk A. Efficacy of 3,5‐dibromo‐L‐phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit. British Journal Of Pharmacology 2009, 158: 2005-2013. PMID: 20050189, PMCID: PMC2807662, DOI: 10.1111/j.1476-5381.2009.00498.x.Peer-Reviewed Original ResearchConceptsSensorimotor gating deficitsEndothelin-1Prepulse inhibitionMK-801Rat modelGating deficitsN-methyl-D-aspartate (NMDA) receptor antagonist dizocilpineDisruption of PPINeuropsychiatric disordersSelective glutamate receptor antagonistsArterial blood pressureMiddle cerebral arteryGlutamate receptor antagonistsSerious side effectsFurther clinical developmentPentylenetetrazole injectionBlood pressureCerebral arteryGlutamatergic activityGlutamatergic agentsIntracerebral injectionReceptor antagonistBrain damageBrain injuryNMDA antagonistsCandesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusion
Mecca AP, O'Connor TE, Katovich MJ, Sumners C. Candesartan pretreatment is cerebroprotective in a rat model of endothelin‐1‐induced middle cerebral artery occlusion. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2009, 94: 937-946. PMID: 19429641, PMCID: PMC2742297, DOI: 10.1113/expphysiol.2009.047936.Peer-Reviewed Original ResearchConceptsAng II type 1 receptor blockerIschemic strokeEndothelin-1-induced middle cerebral artery occlusionMiddle cerebral artery occlusion modelBrain renin-angiotensin systemType 1 receptor blockerMiddle cerebral artery occlusionIpsilateral gray matterCerebral artery occlusionRenin-angiotensin systemArtery occlusion modelAnimal stroke modelsSignificant neurological impairmentCandesartan pretreatmentCerebroprotective propertiesGradual reperfusionEmbolic strokeArtery occlusionNeurological deficitsReceptor blockersSystemic pretreatmentBlood pressureCerebral ischaemiaMCAO modelInfarct size
2007
Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertension
Grobe J, Mecca A, Lingis M, Shenoy V, Bolton T, Machado J, Speth R, Raizada M, Katovich M. Angiotensin‐(1–7) prevents cardiac remodeling during angiotensin II‐induced hypertension. The FASEB Journal 2007, 21: a896-a897. DOI: 10.1096/fasebj.21.6.a896-d.Peer-Reviewed Original ResearchAng IICardiac remodelingBlood pressureInterstitial fibrosisMyocyte hypertrophyMale Sprague-Dawley ratsAng II infusionAnti-remodeling effectsEnd-organ damageRenin-angiotensin systemSprague-Dawley ratsII infusionAng receptorsAngiotensin receptorsAngiotensin IIMyocardial fibrosisRat modelMyocyte diameterEnzyme 2Receptor populationAngHypertensionFibrosisSignificant attenuationLentiviral delivery
2006
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)
Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). AJP Heart And Circulatory Physiology 2006, 292: h736-h742. PMID: 17098828, DOI: 10.1152/ajpheart.00937.2006.Peer-Reviewed Original ResearchMeSH KeywordsAnalysis of VarianceAngiotensin IAngiotensin IIAnimalsBlood PressureCardiomegalyDisease Models, AnimalFibrosisHeartHypertensionMaleMyocardiumPeptide FragmentsProto-Oncogene MasProto-Oncogene ProteinsRatsRats, Sprague-DawleyReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Receptors, G-Protein-CoupledTime FactorsTransforming Growth Factor betaVentricular RemodelingConceptsRenin-angiotensin systemCardiac remodelingChronic infusionBlood pressureAng IIHeart failureInterstitial fibrosisAngiotensin IIMyocyte hypertrophyHyperactive renin-angiotensin systemAng II type 1Adult Sprague-Dawley ratsEffects of AngSubsequent heart failureOverexpression of angiotensinAcute myocardial infarctionMajor risk factorFormation of AngSprague-Dawley ratsCardiac tissueSubgroup of animalsChronic hypertensionAng receptorsMyocardial infarctionRisk factorsEffects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats
Mitra A, Katovich MJ, Mecca A, Rowland NE. Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. Physiology & Behavior 2006, 89: 221-225. PMID: 16839572, DOI: 10.1016/j.physbeh.2006.06.006.Peer-Reviewed Original ResearchConceptsBlood pressureFluid intakeRole of apelinHypotensive actionPeripheral administrationAntidipsogenic effectPeripheral injectionSodium appetiteCardiovascular parametersSated ratsAngiotensin peptidesSprague-DawleyUnrestrained ratsApelinFluid homeostasisRatsDisparate effectsIntakeNovel peptideConsistent effectRobust effectPrevious studiesPeptidesAdministrationAppetiteChronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension
Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension. AJP Heart And Circulatory Physiology 2006, 290: h2417-h2423. PMID: 16415071, DOI: 10.1152/ajpheart.01170.2005.Peer-Reviewed Original ResearchConceptsDOCA-salt modelBlood pressureCardiac hypertrophyCardiac fibrosisCardiac remodelingDeoxycorticosterone acetate pelletsDOCA-salt animalsBlood pressure responseCarotid artery cannulationDOCA-salt treatmentTail-cuff methodWk of treatmentPerivascular collagen depositionSprague-Dawley ratsNormal drinking waterAngiotensin fragmentsChronic angiotensinDOCA animalsAngiotensin infusionArtery cannulationPerivascular fibrosisSham surgeryAngiotensin IIOsmotic minipumpsMyocyte diameter
2005
Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats
Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2005, 90: 783-790. PMID: 16049057, DOI: 10.1113/expphysiol.2005.031096.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin-Converting Enzyme 2AnimalsAnimals, NewbornBlood PressureBody WeightCarboxypeptidasesCardiomyopathy, HypertrophicEndomyocardial FibrosisGene ExpressionGenetic VectorsHeartLentivirusMiceMyocardiumOrgan SizePeptidyl-Dipeptidase ARatsRats, Sprague-DawleyTransduction, GeneticConceptsRenin-angiotensin systemAngiotensin IIMyocardial fibrosisCardiac hypertrophyAngiotensin II infusionSystolic blood pressureBody weight ratioOverexpression of ACE2Potential therapeutic targetII infusionMmHg increaseBlood pressureHeart weightControl ratsDawley ratsCardiovascular diseaseEnzyme 2Protective effectTherapeutic targetMouse ACE2FibrosisHypertrophyRatsACE2Significant attenuation